• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD. Expand
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications. Expand
MDS clinical diagnostic criteria for Parkinson's disease
The Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity, and two levels of certainty are delineated: clinically established PD and probable PD. Expand
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
Patients with Parkinson's disease had similar improvement in motor function after either pallidal or subthalamic stimulation, and nonmotor factors may reasonably be included in the selection of surgical target for deep-brain stimulation. Expand
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
The Montreal Cognitive Assessment has adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment or dementia in Parkinson disease, however, a positive screen using either instrument requires additional assessment due to suboptimal specificity at the recommended screening cutoff point. Expand
The Parkinson Progression Marker Initiative (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding ofExpand
The scientific and clinical basis for the treatment of Parkinson disease (2009)
This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of theDifferent approaches. Expand
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically, and the dopamine agonists-associated risk for ICDs in other populations should be assessed. Expand
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo. Expand
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study. Expand